NCT00476645View on ClinicalTrials.gov

Fulvestrant in Hormone Refractory Prostate Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

September 30, 2009

Study Completion Date

December 31, 2009

Conditions

Prostatic NeoplasmsProstate Cancer

Interventions

DRUG

Fulvestrant

Fulvestrant 250 mg IM on Days 1 and 14 in the first month, thereafter 250 mg monthly

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Stanford University

OTHER